GADOTERATE MEGLUMINE Drug Patent Profile
✉ Email this page to a colleague
When do Gadoterate Meglumine patents expire, and what generic alternatives are available?
Gadoterate Meglumine is a drug marketed by Hainan Poly and Hengrui Pharma and is included in two NDAs.
The generic ingredient in GADOTERATE MEGLUMINE is gadoterate meglumine. Four suppliers are listed for this compound. Additional details are available on the gadoterate meglumine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gadoterate Meglumine
A generic version of GADOTERATE MEGLUMINE was approved as gadoterate meglumine by HENGRUI PHARMA on April 11th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GADOTERATE MEGLUMINE?
- What are the global sales for GADOTERATE MEGLUMINE?
- What is Average Wholesale Price for GADOTERATE MEGLUMINE?
Summary for GADOTERATE MEGLUMINE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Clinical Trials: | 15 |
| DailyMed Link: | GADOTERATE MEGLUMINE at DailyMed |
Recent Clinical Trials for GADOTERATE MEGLUMINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bayer | Phase 3 |
| Boehringer Ingelheim | Phase 2 |
| Massachusetts General Hospital | Phase 2 |
Pharmacology for GADOTERATE MEGLUMINE
| Drug Class | Gadolinium-based Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for GADOTERATE MEGLUMINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hainan Poly | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 218073-001 | Jun 17, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hengrui Pharma | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 215304-002 | Apr 11, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hainan Poly | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 218073-004 | Jun 17, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hengrui Pharma | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 215304-003 | Apr 11, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hainan Poly | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 218073-002 | Jun 17, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hainan Poly | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 218073-003 | Jun 17, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
